Aclaris Therapeutics
ACRS
62 hedge funds and large institutions have $46.1M invested in Aclaris Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 21 closing their positions.
38% more capital invested
Capital invested by funds: $33.4M → $46.1M (+$12.7M)
9.31% less ownership
Funds ownership: 77.28% → 67.97% (-9.3%)
13% less funds holding
Funds holding: 71 → 62 (-9)
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$670K |
| 2 |
Millennium Management
New York
|
+$516K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$368K |
| 4 |
Jane Street
New York
|
+$271K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.12M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.19M |
| 3 |
MP
MFN Partners
Boston,
Massachusetts
|
-$886K |
| 4 |
State Street
Boston,
Massachusetts
|
-$789K |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$745K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Legal & General Group
London,
United Kingdom
| – | -$6K | -5,519 | Closed |
|
|
AIP
77
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$2K | -2,238 | Closed |
|
78
Rockefeller Capital Management
New York
| – | -$1K | -1,000 | Closed |
|
79
Simplex Trading
Chicago,
Illinois
| – | +$690 | +515 | New |
|
ACRS Hedge Fund Activity: Q2 2020 in Review
62 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2020, worth a combined $46.1M — up 38% from $33.4M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ACRS and 12 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 13 added.
The largest buyer was Adage Capital Partners, adding an estimated $670K. The largest seller was BlackRock, cutting an estimated $2.12M.
- 62 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2020, down from 71 in Q1 2020.
- Funds reported $46.1M of Aclaris Therapeutics stock for Q2 2020, up 38% quarter-over-quarter.
- 12 funds opened new Aclaris Therapeutics positions in Q2 2020 and 21 closed out, a net change of -9 holders.
- The largest Aclaris Therapeutics buyer in Q2 2020 was Adage Capital Partners, an estimated $670K added.
- The largest Aclaris Therapeutics seller in Q2 2020 was BlackRock, an estimated $2.12M sold.
Based on aggregated 13F filings for Q2 2020.